Results 131 to 140 of about 5,919,627 (334)

Revisiting Mission‐Oriented Cancer Research to tackle the increasing burden of cancer in Europe–a policy perspective

Molecular Oncology, EarlyView.
Translational cancer research and its implementation through competitively selected Comprehensive Cancer Centers across Europe should be the primary policy focus for addressing the increasing cancer burden in Europe and counteract the present main strategy to convert cancer to a chronic disease.
Manuel Heitor, Julio Celis, Ulrik Ringborg   +2 more
wiley   +1 more source

Osteoglycin (OGN) reverses epithelial to mesenchymal transition and invasiveness in colorectal cancer via EGFR/Akt pathway

Journal of Experimental & Clinical Cancer Research, 2018
Background Many types of cancers are devoid of the small leucine-rich proteoglycans: osteoglycin (OGN), but its role in tumorigenesis is poorly studied especially in colorectal cancers (CRC).
Xiang Hu, Ya-Qi Li, Qing-Guo Li, Yan-Lei Ma, Jun-Jie Peng, San-Jun Cai   +5 more
doaj   +1 more source

Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability.

Journal of the National Cancer Institute, 2004
Hereditary nonpolyposis colorectal cancer (HNPCC), also known as Lynch syndrome, is a common autosomal dominant syndrome characterized by early age at onset, neoplastic lesions, and microsatellite instability (MSI).
A. Umar, C. Boland, J. Terdiman, S. Syngal, A. de la Chapelle, J. Rüschoff, R. Fishel, N. Lindor, L. Burgart, R. Hamelin, S. Hamilton, R. Hiatt, J. Jass, A. Lindblom, H. Lynch, P. Peltomaki, S. Ramsey, M. Rodriguez-Bigas, H. Vasen, E. Hawk, J. Barrett, A. Freedman, S. Srivastava   +22 more
semanticscholar   +1 more source

Proteasome inhibitor, ixazomib prevents topoisomerase‐I degradation and reverses irinotecan resistance in colorectal cancer

Molecular Oncology, EarlyView.
Ixazomib inhibits proteasome‐mediated degradation of topoisomerase I induced by irinotecan, thereby restoring drug sensitivity and promoting tumor cell death in colorectal cancer. Irinotecan, a topoisomerase I (topoI) inhibitor, is widely used for colorectal cancer, but resistance remains a major clinical challenge.
Yuho Ebata, Koji Ando, Hirofumi Hasuda, Koshi Mimori, Elizabeth C. Unan, Siddhartha Pulukuri, Aahana Tiku, Allison Berger, Eiji Oki, Ajit Bharti, Tomoharu Yoshizumi   +10 more
wiley   +1 more source

Targeting the tumor microenvironment in colorectal peritoneal metastases

, 2020
Peritoneal metastasis (PM) occurs in approximately one in four colorectal cancer (CRC) patients. The pathophysiology of colorectal PM remains poorly characterized. Also, the efficacy of current treatment modalities, including surgery and intraperitoneal (
Ceelen, Wim, De Wever, Olivier, Heriot, Alexander G., Narasimhan, Vignesh, Ramsay, Robert G.   +4 more
core   +1 more source

Metastasis on pause: How dormant tumor cells stay hidden within the tumor microenvironment and evade immune surveillance

Molecular Oncology, EarlyView.
Dormant cancer cells can hide in distant organs for years, evading treatment and the immune system. This review highlights how signals from the surrounding tissue and immune environment keep these cells inactive or trigger their reawakening. Understanding these mechanisms may help develop therapies to eliminate or control dormant cells and prevent ...
Kanishka Tiwary, Jose Javier Bravo‐Cordero   +1 more
wiley   +1 more source

Meta-analysis of fecal metagenomes reveals global microbial signatures that are specific for colorectal cancer

Nature Medicine, 2019
Association studies have linked microbiome alterations with many human diseases. However, they have not always reported consistent results, thereby necessitating cross-study comparisons.
J. Wirbel, P. Pyl, E. Kartal, Konrad Zych, A. Kashani, A. Milanese, J. S. Fleck, A. Voigt, A. Pallejà, R. Ponnudurai, S. Sunagawa, Luis Pedro Coelho, P. Schrotz-King, E. Vogtmann, N. Habermann, E. Niméus, A. M. Thomas, P. Manghi, S. Gandini, D. Serrano, Sayaka Mizutani, H. Shiroma, Satoshi Shiba, T. Shibata, S. Yachida, Takuji Yamada, L. Waldron, A. Naccarati, N. Segata, R. Sinha, C. Ulrich, H. Brenner, Manimozhiyan Arumugam, P. Bork, G. Zeller   +34 more
semanticscholar   +1 more source

Metachronous colorectal cancers

Journal of British Surgery, 1998
Abstract Background Up to 9 per cent of patients who undergo resection for colorectal cancer develop metachronous cancers. There is no consensus on the detection and management of such cancers. Methods The literature was reviewed ...
O, Fajobi, C Y, Yiu, S B, Sen-Gupta, P B, Boulos   +3 more
openaire   +2 more sources

DNA methylation and expression of MAPRE3 affect overall survival of early‐stage non‐small cell lung cancer patients

Molecular Oncology, EarlyView.
Both cg12821679MAPRE3 methylation and MAPRE3 expression are significantly associated with overall survival (OS) of non‐small cell lung cancer. Meanwhile, MAPRE3 expression significantly modified the effect of smoking cessation on OS. Smoking cessation benefits OS merely for patients with high MAPRE3 expression.
Chao Chen, Jiancheng Cheng, Ruili Hou, Xiaoyuan Zheng, Li Su, Maria Moksnes Bjaanæs, Anna Karlsson, Maria Planck, Johan Staaf, Åslaug Helland, Manel Esteller, David C. Christiani, Feng Chen, Xiaofei Cao, Ruyang Zhang   +14 more
wiley   +1 more source

CNOT7 facilitates radiation resistance in colorectal cancer through TRIM21/XRCC6-mediated non-homologous end joining repair

Cell Death and Disease
Radiotherapy is essential in the treatment of colorectal cancer (CRC), but the presence of drug resistance leads to poor prognosis for CRC patients. Identifying targets and mechanisms for regulating radiotherapy resistance has high clinical value.
Yien Li, Luying Cui, Shaoke Wang, Qunye Zhao, Fenqi Du, Songtao Du, Chenfeng Yu, Mingyu Xia, Shihui Zhao, Tian Luan, Yanlong Liu, Binbin Cui   +11 more
doaj   +1 more source